Ginkgo Bioworks entered a collaboration with Pfizer focused on the discovery of RNA-based drug candidates. Pfizer will leverage Ginkgo’s RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development and commercial milestones, up to a total of $331 million across three programs. Ginkgo is also entitled to potential royalties on sales.   Ginkgo&#8...